Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.
Mautner
V-F
VF
Department of Maxillofacial Surgery. Electronic address: v.mautner@uke.de.
Nguyen
R
R
Department of Maxillofacial Surgery.
Knecht
R
R
Department of Ears, Nose and Throat.
Bokemeyer
C
C
Department of Oncology/Hematology, Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009464:Neuroma, Acoustic / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011859:Radiography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab